Login / Signup

Persistence and Adherence to PCSK9 Inhibitor Monoclonal Antibodies Versus Ezetimibe in Real-World Settings.

Paul MuntnerLama GhaziJenna JonesNafeesa DhalwaniBharat PoudelYing WenLigong ChenZhixin WangVera BittnerBethany KalichMichael E FarkouhMark WoodwardLisandro D ColantonioRobert S Rosenson
Published in: Advances in therapy (2024)
These data suggest approaches to increase persistence and adherence to PCSK9i mAb and ezetimibe should be implemented prior to or within 182 days following treatment initiation.
Keyphrases
  • glycemic control
  • big data
  • type diabetes
  • combination therapy
  • monoclonal antibody
  • adipose tissue
  • deep learning
  • data analysis
  • replacement therapy